UNSPSC 85816330: Introduction of immunostimulator into peripheral vein, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of immunostimulator into peripheral vein, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E033WK

UNSPSC 85816330 Introduction of immunostimulator into peripheral vein, percutaneous approach is a Commodity code with minimal alignment to current state and local procurement activity. The recent opportunities tagged under this code span virtual urgent care services, medical director contracts, cancer screening, employee wellness platforms, nursing home operations, occupational health services, and substance abuse treatment—none of which involve the administration of immunostimulators through intravenous injection as the code nominally describes.

State and local governments are soliciting these opportunities across a broad geographic footprint and issuing body mix: Inland Empire Health Plan (California), DeKalb County (Georgia), Nevada Health Authority, San Mateo County (California), Boulder County (Colorado), City of Ocala (Florida), Cobb County (Georgia), Los Alamos County (New Mexico), Brevard County (Florida), Santa Clara County (California), City of Phoenix (Arizona), Fairfax County (Virginia), Seminole County (Florida), and others. The Inland Empire Health Plan issued an RFI for virtual urgent care services due October 31, 2026, seeking telehealth-based evaluation and medication prescribing for plan members. The Nevada Health Authority issued two concurrent RFPs: Program of All Inclusive Care for the Elderly (PACE) operations across multiple Nevada service areas (proposals due December 10, 2026) with fixed monthly capitation rates ranging from $4,532.24 to $8,804.32 per participant depending on county and eligibility status, and a Rural Value Acceleration Network (RVAN) vendor solicitation (proposals due November 30, 2026) to facilitate statewide value-based care initiatives for rural hospitals and providers. The code shows no substantive recent activity aligned to its formal scope—the opportunities are being categorized under it appear to reflect broader healthcare service procurement rather than the specific clinical procedure this commodity code describes, suggesting either a data-classification issue or dormancy in the actual immunostimulator-injection market at state and local level.